<DOC>
	<DOCNO>NCT01857115</DOCNO>
	<brief_summary>This protocol phase I/II multicenter study design ass safety efficacy propose combination up-front treatment elderly Multiple Myeloma ( MM ) patient .</brief_summary>
	<brief_title>Study Weekly Carfilzomib , Cyclophosphamide Dexamethasone In Newly Diagnosed Multiple Myeloma Patients ( wCCyd )</brief_title>
	<detailed_description>TREATMENT PERIOD Patients start induction treatment wCCyd , soon screen visit pre-treatment period terminate . Each cycle repeat every 28 day total 9 course . Treatment schedule 9 cycle induction : Phase I : In phase I part study , follow dose level carfilzomib study constant dos dexamethasone cyclophosphamide define maximum tolerate dose ( MTD ) : Level -1 1 . Cyclophosphamide give orally dose 300 mg/m2 day 1 , 8 , 15 . 2 . Dexamethasone give orally dose 40 mg day 1 , 8 , 15 , 22 20 mg day 1-2 , 8-9,15-16 , 22-23 . 3 . Carfilzomib give 20 mg/m2 IV daily Day 1 Cycle 1 follow 36 mg/m2 day 8 , 15 Cycle 1 , subsequent dose 36 mg/m2 IV daily day 1 , 8 , 15 , follow 14-day rest period ( day 16 28 ) . Level 0 ( start dose ) 1 . Cyclophosphamide give orally dose 300 mg/m2 day 1 , 8 , 15 . 2 . Dexamethasone give orally dose 40 mg day 1 , 8 , 15 , 22 20 mg day 1-2 , 8-9,15-16 , 22-23 . 3 . Carfilzomib give 20 mg/m2 IV daily Day 1 Cycle 1 follow 45 mg/m2 day 8 , 15 Cycle 1 , subsequent dose 45 mg/m2 IV daily day 1 , 8 , 15 , follow 14-day rest period ( day 16 28 ) . Level +1 1 . Cyclophosphamide give orally dose 300 mg/m2 day 1 , 8 , 15 . 2 . Dexamethasone give orally dose 40 mg day 1 , 8 , 15 , 22 20 mg day 1-2 , 8-9,15-16 , 22-23 . 3 . Carfilzomib give 20 mg/m2 IV daily Day 1 Cycle 1 follow 56 mg/m2 day 8 , 15 Cycle 1 , subsequent dose 56 mg/m2 IV daily day 1 , 8 , 15 , follow 14-day rest period ( day 16 28 ) . Level +2 1 . Cyclophosphamide give orally dose 300 mg/m2 day 1 , 8 , 15 . 2 . Dexamethasone give orally dose 40 mg day 1 , 8 , 15 , 22 20 mg day 1-2 , 8-9,15-16 , 22-23 . 3 . Carfilzomib give 20 mg/m2 IV daily Day 1 Cycle 1 follow 70 mg/m2 day 8 , 15 Cycle 1 , subsequent dose 70 mg/m2 IV daily day 1 , 8 , 15 , follow 14-day rest period ( day 16 28 ) . Patients observe first cycle therapy assessment side effect observation DLTs . Dose escalation proceed follow : - 3 patient enter dose level 0 . - If 0/3 patient experience DLT , dose escalation continue . - If 1/3 patient experience DLT , 3 additional patient add cohort ( max 6 ) . - If patient experience DLT ( 1/6 ) dose escalation continue . - If 2/6 patient experience DLT , MTD exceed MTD previous dose &lt; 2/6 experienced DLT . - If 2/3 patient experience DLT give dose , MTD exceed MTD precede dose &lt; 2/6 ( 1/3 ) patient experience DLT . Phase II : The dose use treat patient phase II MTD define phase I study . MAINTENANCE PERIOD At end induction phase , patient start maintenance phase Carfilzomib MTD define phase I study IV daily day 1 , 8 , 15 progression intolerance . Treatment schedule maintenance progression intolerance : Carfilzomib MTD define phase I study IV daily day 1 , 8 , 15 .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Diseaserelated 1 . Patient newly diagnose MM patient . 2 . Patient age ≥ 65 year age ineligible autologous stem cell transplantation . 3 . Patient measurable disease , define follow : quantifiable serum monoclonal protein value ( generally , necessarily , ≥ 0.5 g/dL Mprotein ) , applicable , urine lightchain excretion &gt; 200 mg/24 hour . For patient oligo nonsecretory MM , require measurable plasmacytoma &gt; 2 cm determine clinical examination applicable radiograph ( i.e . MRI , CTScan ) abnormal free light chain ratio ( n.v. : 0.261.65 ) . We anticipate less 10 % patient admit study oligo nonsecretory MM free light chain order maximize interpretation benefit result . Demographic : 4 . Age ≥ 18 year . 5 . Life expectancy ≥ 3 month . 6 . Eastern Cooperative Oncology Group ( ECOG ) performance status 02 ( Appendix F ) . Laboratory : 7 . Adequate hepatic function , serum ALT ≤ 3.5 time upper limit normal serum direct bilirubin ≤ 2 mg/dL ( 34 µmol/L ) within 14 day prior randomization . 8 . Absolute neutrophil count ( ANC ) ≥ 1.0 × 109/L within 14 day prior randomization . 9 . Corrected serum calcium ≤ 14 mg/dL ( 3.5 mmol/L ) . 10 . Alanine transaminase ( ALT ) : ≤ 3 x ULN . 11 . Hemoglobin ≥ 8 g/dL ( 80 g/L ) within 14 day prior randomization ( subject may receive red blood cell [ RBC ] transfusion accordance institutional guideline ) . 12 . Platelet count ≥ 50 × 109/L ( ≥ 30 × 109/L myeloma involvement bone marrow &gt; 50 % ) within 14 day prior randomization . 13 . Creatinine clearance ( CrCl ) ≥ 15 mL/minute within 7 day prior randomization , either measure calculate use standard formula ( eg , Cockcroft Gault ) . Ethical/Other : 14 . Written inform consent accordance federal , local , institutional guideline . 15 . Females childbearing potential ( FCBP ) must agree ongoing pregnancy test practice contraception . 16 . Male subject must agree practice contraception . Diseaserelated : 1 . Previous treatment antimyeloma therapy ( include radiotherapy , bisphosphonates , single short course steroid ; ≤ equivalent dexamethasone 40 mg/day 4 day ) 2 . Patient relapse refractory multiple myeloma . 3 . Patients nonsecretory MM unless serum free light chain present ratio abnormal . Concurrent Conditions : 4 . Pregnant lactating female ( Appendix I ) . 5 . Major surgery within 21 day prior randomization . 6 . Acute active infection require treatment ( systemic antibiotic , antiviral , antifungal ) within 14 day prior randomization . 7 . Known human immunodeficiency virus infection . 8 . Active hepatitis B C infection . 9 . Unstable angina myocardial infarction within 4 month prior randomization , NYHA Class III IV heart failure , uncontrolled angina , history severe coronary artery disease , severe uncontrolled ventricular arrhythmia , sick sinus syndrome , electrocardiographic evidence acute ischemia Grade 3 conduction system abnormalities unless subject pacemaker . 10 . Uncontrolled hypertension , uncontrolled congestive heart failure ( CHF ) uncontrolled diabetes within 14 day prior randomization . 11 . Nonhematologic malignancy within past 3 year exception ) adequately treat basal cell carcinoma , squamous cell skin cancer , thyroid cancer ; b ) carcinoma situ cervix breast ; c ) prostate cancer Gleason Grade 6 less stable prostatespecific antigen level ; ) cancer consider cure surgical resection unlikely impact survival duration study , localize transitional cell carcinoma bladder benign tumor adrenal pancreas . 12 . Significant neuropathy ( Grades 34 , Grade 2 pain ) within 14 day prior randomization . 13 . Known history allergy Captisol® ( cyclodextrin derivative use solubilize carfilzomib ) . 14 . Contraindication require concomitant drug supportive treatment , include hypersensitivity anticoagulation antiplatelet option , antiviral drug , intolerance hydration due preexist pulmonary cardiac impairment . 15 . Subjects pleural effusion require thoracentesis ascites require paracentesis within 14 day prior randomization . 16 . Any clinically significant medical disease condition , Investigator 's opinion , may interfere protocol adherence subject 's ability give inform consent .</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Multiple myeloma</keyword>
	<keyword>Diagnosis</keyword>
	<keyword>Weekly</keyword>
	<keyword>CCyd</keyword>
</DOC>